The Death Cross Is Lying: Why Wall Street Is Still Loading Up on Hershey and Vertex

The death crosses flashing on both Hershey (NYSE: HSY | HSY Price Prediction) and Vertex Pharmaceuticals (NASDAQ: VRTX) are a bearish technical signal that Wall Street is openly ignoring. Analyst consensus on both stocks is solidly bullish, with double-digit implied upside to consensus targets, and the institutional bid keeps appearing even as the 50-day moving averages drift below the 200-day lines.

What the Smart Money Actually Thinks of Hershey

Let’s start with Hershey. The stock closed at $180.84 on June 11, 2026, while the consensus analyst target price is $217.14. The ratings skew cautiously positive. Critically, the death cross itself is razor-thin, with the 50-day moving average at $193.09 versus the 200-day at $193.97. That is a separation of less than a dollar on a stock trading in the $180s. The signal is mechanically valid but informationally weak.

The fundamentals behind the analyst optimism are concrete. Hershey delivered Q1 FY2026 adjusted EPS of $2.35, a 14.67% beat over the $2.05 estimate. Revenue totaled $3.10 billion after growing 10.65% year over year. Management reaffirmed FY2026 guidance for adjusted EPS of $8.20 to $8.52, implying low-double-digit growth for the full year. At a forward P/E of 21 and a trailing P/E of 33, the market is already pricing in earnings normalization. The 3.2% dividend yield and beta of 0.081 make this one of the lowest-volatility names in consumer defensive coverage.

Vertex Offers an Even Louder Buy Signal

Vertex Pharmaceuticals presents an even more lopsided picture. The consensus target price is $548.69, versus a closing price of $445.04 on June 11, 2026. The rating split is overwhelmingly bullish, and the death cross is similarly cosmetic, with the 50-day moving average at $436.72 against the 200-day at $437.41. Meanwhile, the stock has been recovering, up fractionally over the past week and 2.1% on the most recent session. The slower 200-day line is catching down to a stock that has already started repairing.

Earnings momentum supports the consensus. Vertex posted Q1 2026 non-GAAP EPS of $4.47 against a $4.31 estimate, with operating income up 80.62% year over year. Non-CF products contributed more than 25% of quarterly growth, validating the diversification thesis. Cash reached $7.247 billion, up 55.02% year over year. The povetacicept BLA for IgA nephropathy is moving through a Priority Review Voucher, six-month expedited review, a near-term regulatory catalyst the technicals do not reflect.

The Disconnect Between Price and Thesis

The key question for retail investors is what to do when a lagging signal disagrees with a forward-looking consensus. On Hershey, the implied move to the analyst target is material, and the name trades well below its 52-week high of $239.48. On Vertex, the same gap is wider still, and the stock trades well below its 52-week high of $507.92. Institutional ownership of 88% for Hershey and 98% for Vertex indicates that professional investors have not been exiting their positions in any significant size.

The Takeaway

A death cross describes price behavior that has already occurred. The Wall Street view, supported by earnings beats, reaffirmed guidance, and active pipeline catalysts, suggests the technical signal is late and marginal in both cases. The smart money is positioned for mean reversion higher, not continuation lower.

Risk remains: a fresh negative catalyst extends the downtrend on either name, and consensus targets are projections, not promises. But on the weight of evidence currently available, the bearish chart pattern is the noisier signal, and the bullish analyst consensus is the cleaner one.